Evidence map›Paper›PMID 36840445›Full record

ArticleESC heart failure2023

Fibrosis-4 index identifies worsening renal function associated with adverse outcomes in acute heart failure.

Kosuke Tsuda, Daichi Maeda, Yumiko Kanzaki, Kazushi Sakane, Takahiro Okuno, Sayuri Nakayama, Daisuke Tokura, Hitomi Hasegawa, Masaaki Hoshiga

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kosuke TsudaDepartment of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan.ORCID 0000-0002-8987-661X
Daichi MaedaDepartment of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Yumiko KanzakiDepartment of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Kazushi SakaneDepartment of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Takahiro OkunoDepartment of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Sayuri NakayamaDepartment of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Daisuke TokuraDepartment of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Hitomi HasegawaDepartment of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Masaaki HoshigaDepartment of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Osaka University of Pharmaceutical Sciences · JPHokushin General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWorsening renal function (WRF) often develops during heart failure (HF) treatment. However, prognostic implications of WRF in acute HF remain controversial, and risk stratification of WRF is challenging. Although the fibrosis-4 index (FIB-4) was initially established as a liver fibrosis marker, recent studies show that high FIB-4 is associated with venous congestion and poor prognosis in acute HF. This study aimed to evaluate whether FIB-4 could identify prognostically relevant and non-relevant WRF in patients with acute HF. METHODS AND

resultsWe retrospectively analysed data from a single-centre registry on acute HF at our university hospital between January 2015 and June 2021. This study included patients with acute HF aged ≥20 years who were immediately hospitalized and had brain natriuretic peptide levels ≥100 pg/mL at admission. WRF was defined as increases of ≥0.3 mg/dL and >25% in serum creatinine level from admission to discharge. FIB-4 scores were calculated before discharge. The primary endpoint was all-cause mortality within 1 year of discharge. Based on the presence of WRF and whether FIB-4 scores were above the median, patients were stratified into four groups: no WRF and lower FIB-4 scores, no WRF and higher FIB-4 scores, WRF and lower FIB-4 scores, and WRF and higher FIB-4 scores. The patients were followed up via clinical visits or telephone interviews. Clinical outcomes were collected from the electronic medical records.

resultsOf the 969 patients hospitalized for acute HF (76 ± 11 years, 59% men), 118 patients (12%) had WRF at discharge. The median (interquartile range) FIB-4 score at discharge was 2.36 (1.55-3.25). The primary endpoint occurred in 136 patients (14.0%). The 1 year mortality rates were 10.5% in the no WRF and lower FIB-4 scores (≤2.36) group (n = 428), 16.1% in the no WRF and higher FIB-4 scores (>2.36) group (n = 423), 12.5% in the WRF and lower FIB-4 scores group (n = 56), and 25.8% in the WRF and higher FIB-4 scores group (n = 62) (P = 0.005). Kaplan-Meier analysis demonstrated higher all-cause mortality in the WRF and higher FIB-4 group (log-rank P = 0.003). In the Cox regression analysis, only the WRF and higher FIB-4 scores group was associated with an increased risk of mortality compared with the no WRF and lower FIB-4 scores group (hazard ratio = 2.11, 95% confidence interval: 1.07-4.18, P = 0.032), despite adjusting for other confounding factors.

conclusionsFIB-4 is a valuable risk stratification marker for WRF in patients with acute HF. The underlying mechanism and potential clinical importance of these observations require further investigation.

Indexed as

Heart FailureFemaleFibrosisHumansKidneyMalePrognosisRetrospective StudiesAcute heart failureBiomarkerFibrosis-4 indexWorsening renal function

Identifiers

PMID36840445
PMCPMC10192251
OpenAlexW4321997031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.